Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Effectiveness of BBV152 vaccine and ChAdOx1-S vaccine in preventing severe disease among vaccinated patients admitted to a designated COVID-19 hospital in India

  • Rajaraman Nivetha (Department of Community Medicine, Tagore Medical College and Hospital) ;
  • Ramesh Anshul (Department of Psychiatry, Sri Muthukumaran Medical College Hospital and Research Institute) ;
  • Subbarayan Sarojini (Department of Paediatrics, Sri Muthukumaran Medical College Hospital and Research Institute) ;
  • Chinnaian Sivagurunathan (Department of Community Medicine, Tagore Medical College and Hospital) ;
  • Chandrasekar Janaganbose Maikandaan (Department of Psychiatry, Melmaruvathur Adhiparasakthi Institute of Medical Sciences & Research)
  • Received : 2023.05.23
  • Accepted : 2024.01.17
  • Published : 2024.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Coronavirus disease 2019 (COVID-19) is a highly formidable disease. Globally, multiple vaccines have been developed to prevent and manage this disease. However, the periodic mutations of severe acute respiratory syndrome coronavirus 2 variants cast doubt on the effectiveness of commonly used vaccines in mitigating severe disease in the Indian population. This study aimed to assess the effectiveness of the BBV152 vaccine and ChAdOx1-S vaccine in preventing severe forms of the disease. Materials and Methods: This retrospective study, based on hospital records, was conducted on 204 vaccinated COVID-19 patients using a consecutive sampling approach. Data on their vaccination status, comorbidities, and high-resolution computed tomography lung reports' computed tomography severity scores were extracted from their medical records. Fisher's exact test and binomial logistic regression analysis were employed to assess the independent associations of various factors with the dependent variables. Results: Of the 204 records, 57.9% represented males, with a mean age of 61.5±9.8 years. Both vaccines demonstrated effective protection against severe illness (90.2%), with BBV152 offering slightly better protection compared to ChAdOx1-S. Male gender, partial vaccination, comorbid conditions, and the type of vaccine were identified as independent predictors of severe lung involvement. Conclusion: This study indicates that both vaccines were highly effective (90%) in preventing severe forms of the disease in fully vaccinated individuals. When comparing the two vaccines, BBV152 was slightly more effective than ChAdOx1-S in preventing severe COVID-19.

Keywords

Acknowledgement

We would like to express our sincere gratitude to the Dean and Medical Superintendent of Tagore Medical College and Hospital for granting us permission to utilize the data for our research. We appreciate their valuable support.

References

  1. WHO Director-General's opening remarks at the media briefing on COVID-19: 11 March 2020 [Internet]. Geneva: World Health Organization; 2020 [cited 2023 May 6]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
  2. Chang D, Chang X, He Y, Tan KJ. The determinants of COVID-19 morbidity and mortality across countries. Sci Rep 2022;12:5888.
  3. World Health Organization (WHO) Emergency Use Authorization (EUA) qualified COVID-19 vaccines [Internet]. Vancouver (BC): BC Centre for Disease Control; 2023 [cited 2023 May 6]. Available from: http://www.bccdc.ca/Health-Info-Site/Documents/COVID-19_vaccine/WHO-EUA-qualified-covid-vaccines.pdf
  4. India: 12 vaccines approved for use in India [Internet]. [place unknown]: COVID19 Vaccine Tracker; c2023 [cited 2023 May 6]. Available from: https://covid19.trackvaccines.org/country/india/
  5. Harder T, Kulper-Schiek W, Reda S, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. Euro Surveill 2021;26:2100920.
  6. Geddes L. India's "Covaxin" vaccine shows high efficacy against COVID-19 infections in phase 3 trial [Internet]. Geneva: Gavi; 2021 [cited 2023 May 6]. Available from: https://www.gavi.org/vaccineswork/indias-covaxin-vaccineshows-high-efficacy-against-covid-19-infections-phase-3
  7. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021;398:1407-16.
  8. Hadizadeh N, Naderi M, Khezri J, Yazdani M, Shamsara M, Hashemi E. Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview. J Diabetes Metab Disord 2022;21:1763-83.
  9. COVAXIN: India's first indigenous COVID-19 vaccine [Internet]. Hyderabad: Bharat Biotech; 2022 [cited 2023 May 6]. Available from: https://www.bharatbiotech.com/covaxin.html
  10. Press statement by the Drugs Controller General of India (DCGI) on restricted emergency approval of COVID-19 virus vaccine [Internet]. New Delhi: Press Information Bureau, Government of India; 2021 [cited 2023 May 6]. Available from: https://www.icmr.gov.in/pdf/press_realease_files/HFW_DCGI_energency_use_authorisation_03012021_2.pdf
  11. All India Institute of Medical Sciences. Protocol for COVID-management: updated version 2.1 - AIIMS 3rd May 2021 [Internet]. New Delhi: AIIMS; 2021 [cited 2023 May 6]. Available from: https://police.py.gov.in/AIIMS%20-%20Version%202.1%20-%20Protocol%20for%20COVID-Management%20-%20Dt%2003.05.21.pdf
  12. Francone M, Iafrate F, Masci GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol 2020;30:6808-17.
  13. Guideline for COVID-19 vaccination of children between 12-14 years of age [Internet]. New Delhi: Ministry of Health and Family Welfare, Government of India; 2022 [cited 2023 May 6]. Available from: https://www.mohfw.gov.in/pdf/GuidelinesCovidvaccination12to14yrchildrenMarch2022.pdf
  14. Sharma R, Thakker V, Bahri Sharma R, et al. Effect of vaccination on the HRCT profile of COVID-19 patients: a single-center experience. J Family Med Prim Care 2022;11:2938-44.
  15. Boehmer TK, DeVies J, Caruso E, et al. Changing age distribution of the COVID-19 pandemic: United States, May-August 2020. MMWR Morb Mortal Wkly Rep 2020;69:1404-9.
  16. Nicoli F, Solis-Soto MT, Paudel D, et al. Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity. Geroscience 2020;42:1015-9.
  17. Kushwaha S, Khanna P, Rajagopal V, Kiran T. Biological attributes of age and gender variations in Indian COVID-19 cases: a retrospective data analysis. Clin Epidemiol Glob Health 2021;11:100788.
  18. Jin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 2020;8:152.
  19. Betron M, Gottert A, Pulerwitz J, Shattuck D, Stevanovic-Fenn N. Men and COVID-19: adding a gender lens. Glob Public Health 2020;15:1090-2.
  20. Gupta N, Kaur H, Yadav PD, et al. Clinical characterization and genomic analysis of samples from COVID-19 break-through infections during the second wave among the various states of India. Viruses 2021;13:1782.
  21. Vaidiyanathan B, Dhanger S, Raajesh J, et al. To determine the clinical efficacy of COVID vaccine in post vaccinated individuals with severe pneumonia in preventing ICU mortality in a COVID designated tertiary care centre: a retrospective study. Arch Anesth Crit Care 2022;8:208-12.
  22. Gurumurthy B, Das SK, Shetty S, Veerabhadrappa RC, Kosinepalli SS, Dharamaraju SH. CT severity score: an imaging biomarker to estimate the severity of COVID-19 pneumonia in vaccinated and non-vaccinated population. Egypt J Radiol Nucl Med 2022;53:88.
  23. Verma A, Kumar I, Singh PK, et al. Initial comparative analysis of pulmonary involvement on HRCT between vaccinated and non-vaccinated subjects of COVID-19. Eur Radiol 2022;32:4275-83.
  24. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect 2022;28:202-21.
  25. Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of covaxin and covishield: a comparative review. Immunol Res 2022;70:289-315.
  26. Singh DD, Parveen A, Yadav DK. SARS-CoV-2: emergence of new variants and effectiveness of vaccines. Front Cell Infect Microbiol 2021;11:777212.
  27. Mohammadi M, Shayestehpour M, Mirzaei H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz J Infect Dis 2021;25:101606.